PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1284% % -20%
Debt-to-equity 8.5% % -27%
Return On Equity -55% % -129%
Return On Assets -51% % -135%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53,211,507 shares 2.8%
Common Stock, Shares, Outstanding 52,993,238 shares 2.4%
Entity Public Float $81,704,068 USD -61%
Weighted Average Number of Shares Outstanding, Basic 52,993,238 shares 2.8%
Weighted Average Number of Shares Outstanding, Diluted 52,993,238 shares 2.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $67,817,000 USD 17%
General and Administrative Expense $24,317,000 USD 16%
Operating Income (Loss) $92,134,000 USD -16%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $84,904,000 USD -26%
Income Tax Expense (Benefit) $6,000 USD -108%
Net Income (Loss) Attributable to Parent $82,705,000 USD -61%
Earnings Per Share, Basic -1 USD/shares -62%
Earnings Per Share, Diluted -1 USD/shares -62%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $36,337,000 USD -26%
Marketable Securities, Current $92,913,000 USD -31%
Cash, Cash Equivalents, and Short-term Investments $129,250,000 USD -35%
Assets, Current $132,449,000 USD -30%
Property, Plant and Equipment, Net $255,000 USD -97%
Operating Lease, Right-of-Use Asset $891,000 USD -89%
Other Assets, Noncurrent $249,000 USD 2.9%
Assets $133,844,000 USD -40%
Accounts Payable, Current $3,399,000 USD 65%
Accrued Liabilities, Current $8,515,000 USD -17%
Liabilities, Current $12,304,000 USD -9.3%
Operating Lease, Liability, Noncurrent $541,000 USD -96%
Liabilities $12,845,000 USD -50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $91,000 USD -78%
Retained Earnings (Accumulated Deficit) $428,417,000 USD -24%
Stockholders' Equity Attributable to Parent $120,999,000 USD -39%
Liabilities and Equity $133,844,000 USD -40%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $18,266,000 USD -13%
Net Cash Provided by (Used in) Financing Activities $10,000 USD
Net Cash Provided by (Used in) Investing Activities $28,714,000 USD 9.7%
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 52,993,238 shares 2.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,465,000 USD 5.2%
Deferred Tax Assets, Valuation Allowance $96,606,000 USD 3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure 0%
Deferred Tax Assets, Gross $96,975,000 USD 0.64%
Operating Lease, Liability $931,000 USD -93%
Depreciation $140,000 USD -90%
Payments to Acquire Property, Plant, and Equipment $4,000 USD -99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $83,024,000 USD -64%
Property, Plant and Equipment, Gross $1,549,000 USD -89%
Operating Lease, Liability, Current $390,000 USD -69%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 132%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $186,000 USD -94%
Deferred Tax Assets, Operating Loss Carryforwards $49,729,000 USD -12%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $3,259,000 USD 2.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $369,000 USD -86%
Share-based Payment Arrangement, Expense $5,830,000 USD -45%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%